Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 6/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 7/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174841 | 0.91 | MEN1 (0.43) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7180141 | 0.91 | ALDH1A1 (0.35) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7184123 | 0.90 | RORC (0.38) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7174823 | 0.88 | RORC (0.42) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7180955 | 0.88 | RECQL (0.36) | ALDH1A1LMNAGAARORCCYP2C9 | |
| SCHEMBL7174655 | 0.87 | RORC (0.37) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7180959 | 0.86 | LMNA (0.36) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7179797 | 0.85 | RORC (0.42) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7180809 | 0.84 | LMNA (0.39) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL7186638 | 0.83 | MEN1 (0.42) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | MAPK13 864/4885MAPK12 993/4885MAPK11 389/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | MAPK13 974/4885MAPK12 1037/4885MAPK11 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.